EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study

Thomas O Crawford iD, Kathryn J Swoboda iD, Darryl C De Vivo iD, Enrico Bertini iD, Wuh-Liang Hwu iD, Richard S Finkel iD, Janbernd Kirschner iD, Nancy L Kuntz iD, Aledie Navas Nazario iD, Julie A Parsons, Astrid Pechmann, Monique M Ryan iD und 14 weitere

Muscle & Nerve · 2023-08 · 68 (2) · 157-170

DOI: 10.1002/mus.27853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, online erschienen am 06.07.2023. Verfasst von Thomas O Crawford und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Spinal Muscular Atrophies of Childhood. Die Arbeit wurde bisher 135-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims NURTURE (NCT02386553) is an open‐label study of nusinersen in children (two SMN2 copies, n = 15; three SMN2 copies, n = 10) who initiated treatment in the presymptomatic stage of spinal muscular atrophy (SMA). A prior analysis after ~3 y showed benefits on survival, respiratory outcomes, motor milestone achievement, and a favorable safety profile. An additional 2 y of follow‐up (data cut: February 15, 2021) are reported.

Methods

The primary endpoint is time to death or respiratory intervention (≥6 h/day continuously for ≥7 days or tracheostomy). Secondary outcomes include overall survival, motor function, and safety.

Results

Median age of children was 4.9 (3.8–5.5) y at last visit. No children have discontinued the study or treatment. All were alive. No additional children utilized respiratory intervention (defined per primary endpoint) since the prior data cut. Children with three SMN2 copies achieved all World Health Organization (WHO) motor milestones, with all but one milestone in one child within normal developmental timeframes. All 15 children with two SMN2 copies achieved sitting without support, 14/15 walking with assistance, and 13/15 walking alone. Mean Hammersmith Functional Motor Scale Expanded total scores showed continued improvement. Subgroups with two SMN2 copies, minimum baseline compound muscle action potential amplitude ≥2 mV, and no baseline areflexia had better motor and nonmotor outcomes versus all children with two SMN2 copies.

Discussion

These results demonstrate the value of early treatment, durability of treatment effect, and favorable safety profile after ~5 y of nusinersen treatment. Inclusion/exclusion criteria and baseline characteristics should be considered when interpreting presymptomatic SMA trial data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalSpinal Muscular Atrophies of ChildhoodChildHumansOligonucleotidesWalking

Stichwörter der Autor:innen

NURTUREmotor functionnusinersensafetyspinal muscular atrophy

Substanzen

nusinersenOligonucleotides

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Departments of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.
  • Unit of Neuromuscular and Neurodegenerative Disorders, Post-Graduate Bambino Gesù Children's Research Hospital, IRCCS, Rome, Italy.
  • Departments of Medical Genetics and Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
  • Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

ORCID-Profile: Thomas O Crawford, Kathryn J Swoboda, Darryl C De Vivo, Enrico Bertini, Wuh-Liang Hwu, Richard S Finkel, Janbernd Kirschner, Nancy L Kuntz, Aledie Navas Nazario, Monique M Ryan, Russell J Butterfield, Haluk Topaloglu, Tawfeg Ben-Omran, Valeria A Sansone, Yuh-Jyh Jong, Angela D Paradis, Zdenek Berger

Förderung

  • NHLBI NIH HHS
  • Biogen

Zitieren

APA

Crawford, T. O., Swoboda, K. J., De Vivo, D. C., Bertini, E., Hwu, W. L., Finkel, R. S., Kirschner, J., Kuntz, N. L., Nazario, A. N., Parsons, J. A., Pechmann, A., Ryan, M. M., Butterfield, R. J., Topaloglu, H., Ben-Omran, T., Sansone, V. A., Jong, Y. J., Shu, F., Zhu, C., …, & NURTURE Study Group (2023). Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study. Muscle & Nerve, 68(2), 157-170. https://doi.org/10.1002/mus.27853

Vancouver

Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study. Muscle & Nerve. 2023;68(2):157-170. doi:10.1002/mus.27853

BibTeX
@article{Crawford2023,
  author = {Crawford, Thomas O and Swoboda, Kathryn J and De Vivo, Darryl C and Bertini, Enrico and Hwu, Wuh-Liang and Finkel, Richard S and Kirschner, Janbernd and Kuntz, Nancy L and Nazario, Aledie Navas and Parsons, Julie A and Pechmann, Astrid and Ryan, Monique M and Butterfield, Russell J and Topaloglu, Haluk and Ben-Omran, Tawfeg and Sansone, Valeria A and Jong, Yuh-Jyh and Shu, Francy and Zhu, Cong and Raynaud, Stephanie and Lago, Tiffany R and Paradis, Angela D and Foster, Richard and Chin, Russell and Berger, Zdenek and NURTURE Study Group, NURTURE Study Group},
  title = {Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study},
  journal = {Muscle & Nerve},
  year = {2023},
  volume = {68},
  number = {2},
  pages = {157--170},
  doi = {10.1002/mus.27853}
}
Kostenlos starten →